The core targets obtained from screening intersecting targets in the PPI network by Cytohubba and CytoNCA plug-ins, of which the top three occupied by AKT1, STAT3, and TP53, were predicted to be the possible main targets of action of the QSDH drug formulary for the treatment of MG. Here, TP53 is linked to myasthenia gravis.